Formulating elafibranor and obeticholic acid with phospholipids decreases drug-induced association of SPARC to extracellular vesicles from LX-2 human hepatic stellate cells-Reference-Cited by-同舟云学术

Formulating elafibranor and obeticholic acid with phospholipids decreases drug-induced association of SPARC to extracellular vesicles from LX-2 human hepatic stellate cells

Published:2023-01 Issue: Volume:182 Page:32-40
ISSN:0939-6411
Container-title:European Journal of Pharmaceutics and Biopharmaceutics
language:en
Short-container-title:European Journal of Pharmaceutics and Biopharmaceutics

Author:

Zivko Cristina,Witt Finja,Koeberle Andreas,Fuhrmann Gregor,Luciani Paola

Funder

Bundesministerium für Bildung und Forschung

Phospholipid Research Center

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Medicine,Biotechnology

Reference63 articles.

1. Burden of liver diseases in the world;Asrani;J. Hepatol.,2019

2. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies;Pimpin;J. Hepatol.,2018

3. N. Ndugga, T.G. Lightbourne, K. Javaherian, J. Cabezas, N. Verma, A.S. Barritt, R. Bataller, Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA, BMJ Open. 7 (2017) e013620. https://doi.org/10.1136/bmjopen-2016-013620.

4. R.A. Vreman, A.J. Goodell, L.A. Rodriguez, T.C. Porco, R.H. Lustig, J.G. Kahn, Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: A microsimulation model, BMJ Open. 7 (2017) e013543. https://doi.org/10.1136/bmjopen-2016-013543.

5. World Gastroenterology Organisation Global Guidelines;LaBrecque;J. Clin. Gastroenterol.,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 3D‐Printed Lipid Mesophases for the Treatment of Chronic Liver Disease;Advanced Materials Technologies;2024-02-21

2. Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling;Biomedicine & Pharmacotherapy;2023-12

3. Polyenylphosphatidylcholine as bioactive excipient in tablets for the treatment of liver fibrosis;International Journal of Pharmaceutics;2023-11

4. Lipid Profiling in Alzheimer’s Disease;Advances in Experimental Medicine and Biology;2023